Kevin Ramdas

Director, Clinical Operations • Longeveron

Dr. Kevin N. Ramdas, MD, MPH is the Director of Medical Affairs at Longeveron Inc., leading the clinical trial division. Longeveron Inc. was founded in 2014 and was publically listed on the Nasdaq in 2021 as a clinical-stage biotechnology company developing cellular therapies for chronic diseases associated with aging and other life-threatening conditions. The lead investigational product, Lomecel-B™, is derived from culture-expanded medicinal signaling cells (MSCs) isolated from the donated bone marrow of young healthy adults. The current clinical pipeline includes Aging/Frailty, Alzheimer’s disease, metabolic syndrome, Hypoplastic left heart syndrome, and ARDS.  Dr. Ramdas attended The Florida State University in Tallahassee, FL for undergraduate studies. He completed medical school basic science training at American University of Antigua and matriculated to Chicago to complete his clinical rotations and externships at RUSH University affiliated hospitals. Following medical school, Dr. Ramdas began his career in clinical research, trial management and academic medicine at the University of Miami (UM), Miller School of Medicine. While managing and coordinating in- and outpatient clinical trials at UM as well as Jackson Memorial Hospital he completed his Masters in Public Health with a concentration on disease prevention and health promotion.  Dr. Ramdas’ immediate past role at the University of Miami was as a Quality Assurance officer at the Interdisciplinary Stem Cell Institute and the Department of Neurology and Neurological Surgery implementing and instituting control systems according to national and regional governing guidelines.

Also Speaking

Robert Hughes

Vice President & General Manager • Miltenyi Biotec

Julie Lenzer

Chief Innovation Officer • ARMI | BioFabUSA

Li Ou

Vice President • Genemagic Bio

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.